The present invention relates to novel antibody heteroconjugates and bispecific antibodies
and methods and compositions and their use in the enhancement or inhibition of activation …

The invention provides bispeci? c antibodies With selective cytotoxicity against malignant B-
cells. The bispeci? c anti bodies bind to an effector cell antigen and to a 28/32 kDa …

This invention relates generally to the field of immunology, in particular that of antibodies
and antibody productions. More Specifically, this invention relates to bispecific antibodies …

57 ABSTRACT A novel cytokine, designated Apo-2 ligand, which induces mammalian cell
apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine …

Bispecific molecules which react both with the high-affinity Fcγ receptor of human effector
cells and with a target cell surface antigen are disclosed. Binding of the molecules to the Fc …

LNAZSHAWQACDHT-XIYTZBAFSA-N (2R, 3R, 4S, 5R, 6S)-4, 5-dimethoxy-2-
(methoxymethyl)-3-[(2S, 3R, 4S, 5R, 6R)-3, 4, 5-trimethoxy-6-(methoxymethyl) oxan-2-yl] oxy …

57 ABSTRACT A novel cytokine, designated Apo-2 ligand, which induces mammalian cell
apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine …

Disclosed are immunopotentiating agents, and vaccines thereof, which enhance and/or
otherwise modify immune responses, and methods for their preparation and use in vivo …

Disclosed are immunopotentiating agents, and vaccines thereof, which enhance and/or
otherwise modify immune responses, and method for their preparation and use in vivo …

BACKGROUND Delivery of therapeutic agents to a mammalian host can frequently be as
important as the activity of the drug in providing effective treatment. For the most part, drugs …